Release Date: April 1, 2018
Date of Most Recent Review: March 31, 2019
Expiration Date: March 31, 2020
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Contact Hours: .5, all of which is eligible for pharmacotherapeutic credit
Participants will receive credit after watching the entire presentation, completing the post-test with a passing grade (70% or greater), and completing an evaluation. Participants may retake the post-test until a passing score is achieved.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for opioid education.
Content for this module was developed in collaboration with Granite Health, Concord, New Hampshire.
Primary care providers and others who prescribe opioids for chronic pain struggle with when and how best to taper patients who are on high doses of opioids in a patient-centered and medically-sound way, while keeping their patients safe and managing their pain. This one-hour program will share best practices in opioid tapering. Identifying when to taper and knowing how to do so will result in improved patient care and reduce the risk of harm associated with high doses of opioids.
At the conclusion of this activity, participants will be better able to assess when and how to taper opioid doses to safely and appropriately manage chronic pain.
Primary and specialty clinicians, nurse practitioners, physician assistants, and nurses involved in the management of patients with chronic pain.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Daniel Alford, MD, MPH (Course Director)
Professor of Medicine
Director, Clinical Addiction Research and Education (CARE) Unit
Boston University School of Medicine
Boston Medical Center
P. Travis Harker, MD (Content Development)
Chief Medical Officer
Appledore Medical Group
Seddon Savage, MD, MS, FASAM (Content Development)
Adjunct Associate Professor of Anesthesiology
Geisel School of Medicine
Dartmouth Medical School
Faculty members have no relevant commercial relationships to disclose.
This presentation does include discussion of the off-label use of clonidine and tizanidine to treat opioid withdrawal symptoms. Clonidine and tizanidine are not FDA approved for this use.
Planners: Ilana Hardesty, BUSM CME Program Manager, has no relevant commercial relationships to disclose.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
© 2019 Trustees of Boston University. Site by Signal.